CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial
NCT ID: NCT03732339
Last Updated: 2022-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
29 participants
INTERVENTIONAL
2018-08-24
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
NCT05360290
The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device
NCT03006055
Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients
NCT00952679
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
NCT06807502
Study of Circulating and Tumor Biomarkers in Breast Cancer Patients
NCT01866202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GILUPI CellCollector®
GILUPI CellCollector®
Use of GILUPI CellCollector® to detect CTC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GILUPI CellCollector®
Use of GILUPI CellCollector® to detect CTC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG 0-1
* Adequate organ function
* Consent to undergo CTC analysis in vivo
Exclusion Criteria
* Metastatic or recurrent patients
* Uncontrollable infection
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Viroad Biotechnology Co., Ltd.
INDUSTRY
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jinsong Lu
Chief of Breast Surgery Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinsong Lu
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RenJiH-2018-038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.